Cancer development and mortality differences in patients with glomerulonephritis after renal biopsy: a single center retrospective cohort study

Table 3 Risk factors related to cancer development after renal biopsy

	Variables	B	Wald	Hazard ratio	95% Confidence interval		P-value
Model 1	IgAN (presence)	− 0.86	6.43	0.43	0.22	0.82	0.01
	Amyloidosis (presence)	2.05	4.05	7.76	1.06	57.05	0.04
	MN (presence)	0.82	5.54	2.27	1.15	4.49	0.02
Model 2	MN (presence)	0.88	5.06	2.41	1.12	5.18	0.03
	Age (year)	0.05	14.06	1.05	1.02	1.07	< 0.001
	Hemoglobin (g/dl)	−0.24	7.71	0.79	0.66	0.93	0.01
Model 3	MN (presence)	0.83	4.42	2.30	1.06	4.98	0.03
	Age (year)	0.05	13.31	1.05	1.02	1.07	< 0.001
	Hemoglobin (g/dl)	−0.23	7.35	0.79	0.67	0.94	0.01

IgAN IgA nephropathy; MN Membranous nephropathy
Model 1: a univariate model for pathologic diagnosis by Cox’s hazard proportional model. Model 2: adjusted with age, gender, and clinical parameters related to the incidence of cancer, such as diabetes mellitus, coronary heart disease, smoking status, chronic hepatitis B and C, liver cirrhosis, and levels of hemoglobin and serum creatinine at renal biopsy. Model 3: adjusted with factors included in model 2 and usage of each immunosuppressive agent such as azathioprine, cyclophosphamide, cyclosporine, mycophenolate, steroids, rituximab, and tacrolimus after renal biopsy but before the development of cancer

ISSN: 1471-2369